Pfizer-Backed EV-209 Trial Targets Bladder Preservation in High-Need Cancer Segment
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Phase 2 EV-209 study, officially titled “An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin Plus Pembrolizumab for Bladder Preservation in Participants With Muscle-invasive Bladder Cancer (EV-209),” tests whether this drug combo can control muscle-invasive bladder cancer while allowing patients to keep their bladder. The goal is to see how many patients stay in response and keep their bladder intact after two years, which could reshape care for eligible patients.
The study tests two approved cancer drugs used together: enfortumab vedotin and pembrolizumab. Both are given by IV and aim to shrink or control bladder tumors so that patients may avoid bladder removal surgery and maintain quality of life.
This is an interventional, Phase 2 trial with one treatment group, so all participants receive the same drug combo rather than being randomized. The study is open-label with no blinding, and the main purpose is treatment, not diagnosis, which makes outcomes easier to track but also more exposed to bias.
The trial is listed as recruiting, with initial submission on 13 March 2026, marking the formal start of trial setup and enrollment. The most recent update was filed on 13 April 2026, signaling active study management and potential protocol refinements that investors should watch for future milestones.
For investors, this study matters because Astellas Pharma leads the trial and Pfizer is a key collaborator, tying both to a possible bladder-preserving option in a high-need cancer segment. Positive data could support broader use of the enfortumab vedotin and pembrolizumab combo against rivals in urothelial cancer and may improve sentiment on long-term oncology revenue streams for both partners.
The EV-209 study is ongoing and recently updated, with further details and tracking available on the ClinicalTrials.gov portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.
